Our Pricing

Wegovy Weight Loss Injections: UK Clinical Guide

Published on: June 03, 2026

When you buy Wegovy online UK in stock from Cured Pharmacy, you're accessing genuine semaglutide weight loss injections from £79.00 with transparent upfront pricing and approval from UK-registered prescribers in under 3 minutes. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees every prescription to ensure safe, compliant treatment tailored to your clinical needs.

How Wegovy (Semaglutide) Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics the naturally occurring hormone glucagon-like peptide-1, which regulates appetite by acting on brain regions that control hunger and food intake.

In the landmark STEP 1 clinical trial involving 1,961 adults, participants using semaglutide 2.4 mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. This represents one of the most substantial weight loss outcomes demonstrated in pharmaceutical trials for obesity management.

The medication works by slowing gastric emptying, increasing feelings of fullness after meals, and reducing overall caloric intake [2]. Clinical data shows that approximately 86% of participants in STEP trials achieved at least 5% weight loss, while 69% achieved 10% or greater reduction [1].

Wegovy Dosing Schedule and Treatment Protocol

Wegovy follows a structured dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising therapeutic outcomes. Treatment begins with 0.25 mg once weekly for four weeks, then increases monthly through 0.5 mg, 1.0 mg, and 1.7 mg, reaching the maintenance dose of 2.4 mg by week 17 [3].

This gradual titration approach, validated across the STEP clinical programme, significantly reduces the incidence of nausea and vomiting compared to starting at higher doses. Your UK prescriber will assess your tolerance at each stage and may adjust the escalation timeline based on your individual response and any adverse effects experienced.

Each Wegovy pen is pre-filled for single use and administered subcutaneously in the abdomen, thigh, or upper arm. The injection site should be rotated weekly to prevent lipodystrophy. Patients typically self-administer at home after initial training, with ongoing clinical monitoring through our UK-registered team.

What to Expect During Treatment

Most patients notice reduced appetite within the first two weeks of treatment, though clinically significant weight loss typically becomes apparent after 8-12 weeks at therapeutic doses. NICE guidelines recommend continuing treatment only if at least 5% body weight reduction is achieved after 6 months at the maintenance dose [4].

Regular follow-up assessments with your prescriber ensure treatment remains appropriate and effective. Blood pressure, lipid profiles, and glycaemic markers often improve alongside weight reduction, contributing to overall cardiometabolic health benefits demonstrated in clinical trials [2].

Buy Wegovy Online UK In Stock: Prescription Process

At Cured Pharmacy, the prescription process takes under 3 minutes through our streamlined online consultation. You'll complete a clinical questionnaire covering your medical history, current medications, weight management goals, and any contraindications to semaglutide therapy. This assessment is reviewed by a UK-registered prescriber who determines your suitability for treatment.

All Wegovy prescriptions are issued by GMC-registered doctors or independent prescribers working within their scope of practice and in accordance with GPhC standards. If approved, your prescription is fulfilled by our UK-licensed pharmacy (GPhC 9012511) using genuine Novo Nordisk Wegovy pens sourced through legitimate UK supply chains.

We maintain consistent stock levels and provide transparent availability information before you begin your consultation. Discreet packaging ensures complete privacy, with delivery typically completed within 2-3 working days via tracked courier services.

Eligibility Criteria for Wegovy

To be prescribed Wegovy in the UK, you must have a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea. Certain medical conditions preclude treatment, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastroparesis [3].

Your prescriber will also review contraindications including pregnancy, breastfeeding, diabetic retinopathy complications, and concurrent use of other GLP-1 agonists. Comprehensive medical screening ensures safe, appropriate treatment aligned with MHRA licensing conditions.

Wegovy Side Effects and Safety Profile

The most commonly reported side effects of Wegovy are gastrointestinal, including nausea (44% of participants in STEP 1), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These effects are typically mild to moderate, occurring predominantly during dose escalation, and tend to diminish as treatment continues.

Serious adverse events are rare but include potential risk of pancreatitis, gallbladder disease, and hypoglycaemia when used alongside insulin or sulfonylureas. Clinical trials showed a 2.8% incidence of cholelithiasis compared to 1.2% with placebo [1]. Patients should be counselled to report severe abdominal pain, persistent vomiting, or signs of pancreatitis immediately.

The MHRA and European Medicines Agency continue active pharmacovigilance for semaglutide. Thyroid C-cell tumours were observed in rodent studies, though no causal link has been established in humans [3]. As a precaution, Wegovy remains contraindicated in patients with personal or family history of medullary thyroid carcinoma.

Managing Common Side Effects

To minimise gastrointestinal symptoms, eat smaller, more frequent meals, avoid high-fat foods, and stay well-hydrated. Ginger tea and bland carbohydrates can help manage nausea. If side effects become intolerable, your prescriber may extend the time at your current dose before escalating further.

Most patients find symptoms resolve within 4-6 weeks at each dose level. Persistent or severe side effects warrant clinical review to assess whether dose adjustment or treatment discontinuation is appropriate.

Wegovy vs Mounjaro: Comparing GLP-1 Weight Loss Treatments

Both Wegovy and Mounjaro are injectable medications licensed in the UK for chronic weight management, but they differ in their mechanisms of action. Wegovy contains semaglutide, a selective GLP-1 receptor agonist, whilst Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist that activates two incretin pathways simultaneously [5].

Head-to-head trial data from SURPASS-2 demonstrated that tirzepatide produced greater weight reduction than semaglutide 1.0 mg (used for type 2 diabetes), with the highest tirzepatide dose achieving 11.2 kg average weight loss compared to 5.7 kg with semaglutide [5]. However, direct comparison trials between Wegovy 2.4 mg and Mounjaro at weight loss doses have not yet been published.

Both medications follow weekly injection schedules and share similar side effect profiles, predominantly gastrointestinal. Choice between treatments depends on individual response, tolerability, medical history, and prescriber clinical judgement. Some patients who experience suboptimal results or intolerable side effects with one medication may achieve better outcomes with the alternative.

Wegovy Price UK and Transparent Pharmacy Costs

At Cured Pharmacy, Wegovy is available from £79.00 per pen, with pricing displayed upfront before you begin your clinical consultation. This transparent approach eliminates hidden fees and ensures you understand the full cost of treatment before committing. Prices vary based on your prescribed dose, with the initial 0.25 mg and 0.5 mg doses typically costing less than the maintenance 2.4 mg pens.

We guarantee the lowest prices in the UK for genuine, MHRA-licensed Wegovy sourced directly through legitimate pharmaceutical supply chains. Unlike some providers, we never compromise on medication authenticity or regulatory compliance to reduce costs. Every pen is traceable, stored according to cold chain requirements, and dispensed under the supervision of our superintendent pharmacist.

Treatment duration varies by individual, but most patients require at least 6-12 months to achieve and consolidate clinically meaningful weight loss. Ongoing costs should be considered as part of your weight management plan, alongside lifestyle modifications including dietary changes and increased physical activity, which remain essential components of successful long-term outcomes [4].

Payment Options and Delivery

We accept all major credit and debit cards, with secure payment processing and complete transaction confidentiality. Orders are fulfilled within 24-48 hours of prescription approval, with tracked delivery ensuring your medication arrives safely and discreetly.

All Wegovy shipments use temperature-controlled packaging to maintain the cold chain required for semaglutide stability. Upon receipt, store pens in the refrigerator at 2-8°C and never freeze. Each pen remains stable for up to 28 days at room temperature once in use.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. Retrieved from https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed by the MHRA for chronic weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities. Individual results may vary. Treatment should be used alongside a reduced-calorie diet and increased physical activity.